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The impact of behavioral symptoms associated with Alzheimer’s disease is
substantial.  These symptoms contribute to diminished quality of life for
patients and caregivers and increase the cost of care in nursing homes.  Early
recognition of behavioral symptoms and appropriate treatment are important
for successful management.  Nonpharmacologic strategies remain the
cornerstone of the management of Alzheimer’s disease–related behavioral
symptoms.  However, nonpharmacologic strategies may not be effective for
problem behaviors, and pharmacologic intervention may be necessary.
Relevant articles were identified through various MEDLINE searches with no
date restrictions, with an emphasis on recent studies that used cholinesterase
inhibitors and memantine.  Additional reports of interest were identified from
the reference lists of these articles.  To facilitate cross-study analyses in the
review of cholinesterase inhibitors and memantine, the database search was
limited to randomized, placebo-controlled trials that used the
Neuropsychiatric Inventory to assess behavioral symptoms of Alzheimer’s
disease.  Overall, evidence from trials of cholinesterase inhibitors and
memantine suggests that when these agents are optimized for the various
stages of Alzheimer’s disease, they can also prevent the emergence of
neuropsychiatric symptoms.  Although results from the literature are not
uniformly positive, cholinesterase inhibitors have been shown to produce
significant improvements in behavioral symptoms in patients with both mild-
to-moderate and moderate-to-severe Alzheimer’s disease.  Evidence also
indicates that memantine might be of benefit as an adjunct to long-term
cholinesterase inhibitor treatment in patients with moderate-to-severe
Alzheimer’s disease and that memantine monotherapy may have some
beneficial effects on behavior in patients with mild-to-moderate disease.  Of
importance, although no direct comparisons have been performed, these
agents seem to have an improved safety and tolerability profile compared with
the frequently used antipsychotic drugs.  When nonpharmacologic strategies
are deemed insufficient to ease problem behaviors in patients with Alzheimer’s
disease, treatment with cholinesterase inhibitors, alone or in combination
with memantine as appropriate for the stage of disease, may be considered as
a first-line option in the early pharmacologic management of Alzheimer’s
disease–related behavioral symptoms.
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Alzheimer’s disease is a degenerative brain
disorder that causes cognitive decline, loss of
function, and emergence of behavioral or
neuropsychiatric symptoms.1 It is the most
common cause of dementia in the United States,
affecting about 4.5 million Americans in 2000,2
and is most prevalent in the elderly, occurring in
3% of the population aged 65–74 years, 19% of
the population aged 75–84 years, and in almost
50% of seniors aged 85 years or older.3
Alzheimer’s disease is particularly common
among nursing home residents, with more than
half of those aged 65 years or older having
Alzheimer’s disease or related dementias.4
Alzheimer’s disease follows a predictable
course that usually begins with memory loss.  As
the disease progresses, cognitive impairment
becomes profound and daily functioning skills
decline.  Although typically thought of as
indicative of late-stage disease, behavioral
symptoms can appear early in the course of the
disease, well before clinical diagnosis.  These
symptoms can include social withdrawal,
depression, paranoia, and mood changes.5 A
study of the natural history of Alzheimer’s disease
showed that 53% of patients demonstrated
symptoms of depression an average of 26 months
before diagnosis (Figure 1).5 As the disease
advances, symptoms such as anxiety, irritability,
and agitation become more pronounced.  Nearly
90% of patients with Alzheimer’s disease develop
behavioral symptoms during their illness6; as
many as 40% have symptoms of mild depression,
and up to 66% experience anxiety.7
The behavioral aspects of Alzheimer’s disease
are highly distressing for the patient.  Symptoms
of agitation (including inappropriate motor
activity), apathy, and psychosis (e.g., hallucina-
tions) are common and are exacerbated in the
presence of the patient’s existing disabilities.
Behavioral symptoms further erode independence
and engender feelings of fear, anger, and frus-
tration.  In a survey of patients with Alzheimer’s
disease in residential care in the United Kingdom,
loss of self-esteem and feelings of fear, bewil-
derment, and frustration contributed to depres-
sion and withdrawal.8 More distressing symptoms,
such as agitation, violence, incontinence, and
wandering, often prompt nursing home placement.9
Behavioral symptoms are also a major source of
stress for the caregiver.  Behavioral disturbances
have been shown to be a strong predictor of
caregiver burden10 and are associated with
increased financial hardship for the caregiver
(e.g., loss of income, out-of-pocket expenses for
formal health care or excess costs related to the
caregivers’ health problems).11 Indeed, caregivers
of patients with Alzheimer’s disease often
consider behavioral and psychiatric symptoms to
be the most challenging and distressing aspects
of the disease.12
Nonpharmacologic Management of Behavioral
Symptoms
Nonpharmacologic interventions have the
potential to reduce the frequency and severity of
behavioral symptoms in patients with dementia
who reside in nursing homes.13–26 Although the
choice of technique depends on the target
behavioral symptom, nonpharmacologic tech-
niques target three broad problems:  behaviors
caused by unmet patient needs, those caused by
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Figure 1. Onset of behavioral symptoms of Alzheimer’s
disease relative to time of diagnosis.  (From reference 5.)
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aggravating factors, and those caused by ill-suited
environments.16 For example, removing any
medical causes of problem behaviors (e.g., pain
and delirium), reducing any excess stimulation in
the environment, and eliminating any known
triggers may reduce physical and verbal aggres-
sion.  Use of nonpharmacologic techniques to
manage behaviors in the nursing home helps
physicians, pharmacists, nurses, and staff begin
to view behaviors as symptoms of underlying
medical and environmental problems.  A group of
authors showed that implementation of an
education program that trained providers (e.g.,
nursing home staff, physicians, nurses, nursing
assistants, and other direct care staff) in the use
of structured guidelines to improve the
management of behavioral problems and to
minimize the use of antipsychotic drugs reduced
the number of days of antipsychotic drug use by
72%, with no increase in behavioral symptom
frequency.27 Therefore, nonpharmacologic
strategies can have meaningful benefits, such as a
reduced need for psychotropic drugs.  Table 1
summarizes some of the commonly used
nonpharmacologic techniques and their associated
outcomes.  Several small studies have shown the
often significant benefits of nonpharmacologic
interventions, such as music therapy,16, 18 massage
or aromatherapy,16, 20 and pet therapy.14, 16
The current limitations in our understanding
of the effectiveness of nonpharmacologic
therapies for the management of behavioral
systems in patients with Alzheimer’s disease
result from difficulties in recruiting patients for
large-scale, randomized studies of these
treatments.  This is generally due to reluctance of
caregivers and/or nursing home personnel,
problems with implementation of treatments
resulting from limitations in communication with
patients, and insufficient funding.16 Despite
these limitations, nonpharmacologic interventions
are the preferred first step in the management of
behavioral symptoms.  However, these approaches
are not always completely effective.  When this is
the case, pharmacologic therapy should be
considered.
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Table 1.  Nonpharmacologic Interventions for Behavioral Symptoms of Alzheimer’s Disease
Intervention Type Outcome
Sensory stimulation Evidence exists that aural and physical stimulation
Music therapy16, 18 can significantly reduce agitation and aggression.
Touch therapy (e.g., massage)16, 20 Light therapy may aid sleep disorders and lessen
Bright-light therapy16, 21 severity of sundowning.a
Social contact
One-to-one contact15 Real or simulated social contact can decrease verbal
Pet therapy14, 16 agitation, aggression, and other disruptive behaviors;
Simulated presence therapy (audio or in some studies, effect reached statistical significance.
video of family)15, 16
Environment
Ensure environment is safe (remove sharp Environmental intervention can decrease verbal and 
edges, install safety locks and grab bars)16 physical aggression; may reduce wandering or pacing.
Do not overstimulate patients (reduce glare
and noise)16
Orientation
Maintain a daily routine17, 24 Orientation intervention can significantly increase
Allow patient independence (wash and dress nondependency in activities of daily living and
themselves, keep personal possessions)15 promotes independence; can also reduce disruptive
Simplify all tasks (give instructions, complex behavioral symptoms.
tasks should be attempted in stages)15
Provide calendars, clocks, and newspapers
to orient time23
Distract and redirect patients as needed17, 26
Remove physical restraints16
Recreation
Exercise programs22 Recreation can decrease agitation and aggression;
Walking19, 24 in some studies, effect reached statistical significance.
Sorting19
Group activities, games, and singing13, 25
aSundowning is defined as recurring confusion and increased agitation in the late afternoon or early evening.
Adapted from reference 23.
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Pharmacologic Management of Behavioral
Symptoms
The neurobiologic basis for the effects of
cholinesterase inhibitors and memantine on the
behavioral symptoms of Alzheimer’s disease
remains unclear.  Nevertheless, studies have
alluded to potential substrates for some of the
emotional disturbances of Alzheimer’s disease
and their response to cholinesterase inhibitors.
For example, dysfunctions in the limbic and
paralimbic cortices have been associated with
various neuropsychiatric disturbances in patients
with Alzheimer’s disease.28 Moreover, atrophy of
the occipital lobe has been associated with visual
hallucinations29; hypoperfusion of the frontal and
temporal regions has been linked to apathy,
delusions, and aggression30–32; and hypoperfusion
of the orbitofrontal cortex has been related to
apathy, disinhibition, irritability, and euphoria.33, 34
In addition, similarities between the neuro-
psychiatric symptoms of Alzheimer’s disease and
anticholinergic toxicity, as well as the reported
anatomic distribution of cholinergic deficits in
patients with Alzheimer’s disease, link
cholinergic abnormalities to behavioral
disturbances.35 Specific studies, of course, are
required to elucidate the precise mode of action
whereby cholinesterase inhibitors affect behavior.
However, it could be postulated that through
their ability to ameliorate cholinergic deficits
and/or stabilize or increase cerebral blood
flow,36–38 cholinesterase inhibitors might facilitate
changes that positively affect behavior in patients
with Alzheimer’s disease.
Similarly, reports demonstrating that glucose
metabolism is altered in the frontal, parietal,
and/or temporal lobes of patients with
Alzheimer’s disease who experience agitation,
anxiety, or delusions,39, 40 might suggest
hypothetic targets for the effect of memantine on
behavior.  Again, dedicated studies are needed to
determine the specific mechanisms involved in
the effects of memantine on the behavioral
symptoms of Alzheimer’s disease.
Literature Review Methodology
Randomized, placebo-controlled clinical trials
that evaluated the effectiveness of cholinesterase
inhibitors and/or memantine for the treatment of
Alzheimer’s disease–related behavioral symptoms
were identified using the following methods.
MEDLINE searches were carried out using the
terms Alzheimer’s or Alzheimer, and
neuropsychiatric or NPI or Neuropsychiatric
Inventory, with no date restrictions.  Abstracts or,
where necessary, complete articles were reviewed
to determine whether the study used a
cholinesterase inhibitor and/or memantine for
treatment and whether the Neuropsychiatric
Inventory was used to evaluate symptoms.  Other
reports and abstracts of interest, which used the
Neuropsychiatric Inventory, were identified from
the reference lists of these articles.  The literature
search was current as of August 2006.  As this
review did not constitute a formal meta-analysis
of the data, no assessments for the possible effect
of publication bias were performed.
Restricting the review of cholinesterase
inhibitors and memantine to trials that used the
Neuropsychiatric Inventory was necessary to
allow analysis of efficacy across different studies.
The Neuropsychiatric Inventory is a specific
measure for the frequency and severity of
neuropsychiatric or behavioral symptoms
associated with Alzheimer’s disease.  The original
10-item Neuropsychiatric Inventory assesses
delusions, hallucinations, agitation/aggression,
depression/dysphoria, anxiety, euphoria/elation,
apathy/indifference, disinhibition, irritability/
lability, and aberrant motor behavior, with each
item being scored from 0–12.41 A 12-item
version, specifically modified for nursing home
residents and called the Neuropsychiatric
Inventory Nursing Home version or Neuro-
psychiatric Inventory–NH, is also commonly
used, and assesses all of the above items with the
addition of nighttime behavior and appetite or
eating disorders.42, 43 The total score ranges for
the 10-item Neuropsychiatric Inventory and 12-
item Neuropsychiatric Inventory–NH are 0–120
and 0–144, respectively, with higher scores
indicating greater behavioral impairment.
To put the Neuropsychiatric Inventory scale
into the context of this article, a study of
behavioral changes in patients with Alzheimer’s
disease showed a mean total 10-item Neuro-
psychiatric Inventory score of 9.8 for mild
Alzheimer’s disease (Mini-Mental State
Examination [MMSE] score 21–30), 14.7 for
moderate Alzheimer’s disease (MMSE score
11–20), and 21.9 for severe Alzheimer’s disease
(MMSE 0–10) among their enrolled patients.6 At
present, it is still unclear how much of an
absolute change in Neuropsychiatric Inventory
score constitutes a clinically meaningful
improvement.  As a result, for each randomized,
placebo-controlled study reviewed, the baseline
Neuropsychiatric Inventory score has been
reported to allow interpretation of the change
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from baseline.
Although the approach used for selection of
trials included in this review of cholinesterase
inhibitors and/or memantine was aimed at
facilitating comparison of results obtained with
different drugs, it must be acknowledged that
differences in the design and reporting of
findings in different studies still limits such
comparisons.  One group of authors recently
reviewed limitations in the design and reporting
of results in all controlled clinical trials of
cholinesterase inhibitors for patients with
Alzheimer’s disease.44 Many of the studies
reviewed in this review article were also
evaluated by these investigators.  Although a
detailed analysis of the study design, data
analysis, and approaches to reporting of results is
beyond the scope of this review, it is nevertheless
important to caution readers about the
limitations of comparing different drugs without
the benefit of results from direct head-to-head
comparison studies.
Cholinesterase Inhibitors
The cholinesterase inhibitors—donepezil,
galantamine, and rivastigmine—are all approved
by the United States Food and Drug
Administration (FDA) for the treatment of mild-
to-moderate Alzheimer’s disease and are
recommended as first-line treatment for patients
in these stages of the disease.45 In clinical trials,
these agents have been shown to positively affect
the cognitive and functional symptoms of
Alzheimer’s disease and can also provide
behavioral benefits to patients with this disease.46–55
Indeed, a recent review of the pharmacologic
treatment of behavioral symptoms in dementia
(including vascular and Lewy body dementia)
with cholinesterase inhibitors indicated that most
studies reported small, but statistically
significant, benefits on behavioral symptoms.56
Mild-to-Moderate Alzheimer’s Disease
Randomized, placebo-controlled clinical
studies that used the Neuropsychiatric Inventory
to assess the effects of cholinesterase inhibitors
on behavior in patients with mild-to-moderate
Alzheimer’s disease have been published for
donepezil and galantamine,49, 53, 54 but not for
rivastigmine.  In the donepezil study, patients
received donepezil for 12 weeks in the open-label
phase; they were then randomly assigned to
receive either donepezil 10 mg/day or placebo for
an additional 12 weeks.49 In the open-label
phase, a significant decrease was noted in total
Neuropsychiatric Inventory scores at weeks 6
and 12 compared with baseline (p<0.0001).  At
week 12, all of the individual behavioral
symptoms, including agitation, anxiety, apathy,
depression, and delusions, had significantly
improved compared with baseline (p<0.005),
with the exception of elation.  Patients who
received donepezil after randomization (weeks
12–24) continued to improve, whereas those
patients receiving placebo had a worsening of
behavioral symptoms, leading to an absolute
treatment difference of 6.2 points by week 24
(treatment difference p=0.02; Table 2).  Caregiver
distress associated with behavioral symptoms
also worsened in caregivers of placebo-treated
patients during weeks 12–24, but improved in
caregivers of patients treated with donepezil
(treatment difference p=0.01).
The efficacy of galantamine in reducing
behavioral symptoms in patients with mild-to-
moderate Alzheimer’s disease was evaluated in
two randomized, placebo-controlled clinical
trials.53, 54 The first assessed the efficacy of 5
months of treatment with three doses of
galantamine (8, 16, and 24 mg/day) or placebo.53
After 5 months, Neuropsychiatric Inventory
scores remained at baseline severity in patients
who received treatment with galantamine either
16 or 24 mg/day, but increased from baseline in
patients receiving the lowest dose of 8 mg/day
(mean +2.3 points) or placebo (mean +2.0
points).  In the other trial, a 3-month flexible-
dose study, neither galantamine 24 or 32 mg/day
nor placebo resulted in a substantial change from
baseline in Neuropsychiatric Inventory scores.54
That no effect on behavior was seen in the latter
trial was likely due to the short study duration
and the exclusion of patients with behavioral
problems at baseline.
Recently, the effectiveness of donepezil and
galantamine for treating problem behaviors was
directly compared over 52 weeks in patients with
mild-to-moderate Alzheimer’s disease.61
Although the effect on behavioral symptoms was
a secondary outcome of the study, and no data
were presented in the published article, the
authors stated that assessment of the mean
change in Neuropsychiatric Inventory demon-
strated no significant difference from baseline
between groups at end point.  Of interest, in
another long-term study assessing the efficacy of
donepezil for up to 4 years in patients with mild-
to-moderate Alzheimer’s disease, no significant
differences were observed in mean Neuropsychiatric
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Inventory changes between treated patients and
those receiving placebo.62 However, there are
concerns regarding the validity of these data, as
the study was underpowered, had very high
attrition rates (80% by the end of year 2), and
was designed to include multiple drug washout
periods.63
Results from a meta-analysis of randomized,
placebo-controlled trials investigating the
functional and behavioral effects of several
cholinesterase inhibitors in patients with mild-to-
moderate Alzheimer’s disease were recently
published.64 Six of the 29 trials included in the
overall meta-analysis used the Neuropsychiatric
Inventory to measure neuropsychiatric outcomes:
two galantamine trials (978 and 386 patients,
trial durations 150 and 90 days), one donepezil
trial (286 patients, trial duration 365 days), and
three trials of a newer cholinesterase inhibitor,
metrifonate (408, 605, and 264 patients, trial
durations 168, 168, and 182 days). (Metrifonate
has now been removed from development due to
toxicity issues.)  For these six trials, summary
meta-analysis showed a small but statistically
significant difference of 1.72 points compared
with placebo (95% confidence interval
0.87–2.57).  As a result, the authors concluded
that for patients with mild-to-moderate
Alzheimer’s disease who have neuropsychiatric
symptoms, cholinesterase inhibitors should be
considered as a first-line therapeutic option.64
Moderate-to-Severe Alzheimer’s Disease
At present, donepezil is the only cholinesterase
inhibitor approved by the FDA for the treatment
of severe Alzheimer’s disease.  The efficacy and
safety of donepezil have been assessed in a
randomized, placebo-controlled study of patients
with moderate-to-severe Alzheimer’s disease that
used the Neuropsychiatric Inventory to assess
behavioral symptoms (Table 2).47 In this trial,
total Neuropsychiatric Inventory scores were
improved from baseline by 4.6 points after 6
months of treatment, whereas those in the
placebo group worsened by 1 point (treatment
difference p=0.0005).  Significant improvements
favoring donepezil were seen in the symptoms of
apathy, depression/dysphoria, and anxiety.
Patients in Nursing Homes
To our knowledge, donepezil is the only
cholinesterase inhibitor to have been studied in
prospective, placebo-controlled trials in patients
in nursing homes that used the Neuropsychiatric
Inventory or Neuropsychiatric Inventory–NH as
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Table 2.  Efficacy of Cholinesterase Inhibitors and Memantine on the Behavioral Symptoms of Patients with Alzheimer’s
Disease:  Results from Randomized, Placebo-Controlled Trials That Used the Neuropsychiatric Inventory Scale
Study Maximum Mean Baseline NPI Score
Duration Baseline Dosage Treatment Placebo
Drug (mo) Disease Stage MMSE Score (mg/day) Group Group
Cholinesterase
inhibitors
Donepezil49 6c Mild to moderate 10–27 10 14.3 15.1
Galantamine53 5 Mild to moderate 10–22 16 12.4 11.0
24 11.9
Donepezil47 6 Moderate to severe 5–17 10 19.6 19.3
Donepezil43 6 Mild to severe; 5–26 10 21.0 20.5
nursing home study
Donepezil57 6 Severe; nursing home study 1–10 10 19.0 19.6
Memantine
Memantine58 6 Mild to moderate 10–22 20 11.5 12.2
Donepezil + 6 Moderate to severe 5–14 20 13.4 13.4
memantine59
Memantine60 7 Moderate to severe 3–14 20 21.4 19.5
MMSE = Mini-Mental State Examination; NPI = Neuropsychiatric Inventory; SEM = standard error of the mean; NS = not statistically
significantly different.
aValue shown represents mean change from baseline; SEM values are given when available from the published study.
bp value is for comparison of mean change from baseline for treatment and placebo groups.
cThree months open-label treatment with donepezil, then randomization to receive either donepezil or placebo for 3 months.  Baseline NPI
score shown is score at randomization (i.e., after 3 mo of open-label donepezil).
dIn favor of placebo.
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an outcome measure (Table 2).43, 57 In the first
study, patients in all stages of Alzheimer’s disease
were included (MMSE scores of 5–26), and
concomitant psychotropic drug use was high
(59% and 62% in the donepezil and placebo
groups, respectively).43 Neuropsychiatric
Inventory–NH total scores were improved for
both donepezil-treated patients and those who
received placebo from 4 weeks until study end
point at 6 months (Table 2).  No significant
difference was observed between treatment
groups for total Neuropsychiatric Inventory
scores.  Individual item analysis showed that
donepezil treatment significantly reduced
agitation/aggression compared with placebo
(p=0.04).  The second, more recent, trial
specifically assessed the efficacy of donepezil in
patients with severe Alzheimer’s disease (MMSE
scores of 1–10).57 As in the earlier nursing home
study, concomitant psychotropic drug use was
very common (> 80% of total study population).
At study end point, total Neuropsychiatric
Inventory scores were improved for both
donepezil-treated and placebo-treated patients
(Table 2).  Again, no significant difference was
observed between the donepezil and placebo
treatment groups for total Neuropsychiatric
Inventory scores.
Although rivastigmine has not been studied in
a prospective, placebo-controlled trial in nursing
home patients, a 52-week open-label study
examined behavioral symptoms using the
Neuropsychiatric Inventory–NH scale as the
primary outcome measure.55, 65 Nursing home
residents with an MMSE score of 6–15 inclusive
were enrolled; 77% had at least one behavioral
symptom at baseline, and all were taking
concomitant drugs for one or more comorbidities.
After 26 weeks of rivastigmine treatment, 46% of
patients showed a 30% or greater reduction in
Neuropsychiatric Inventory–NH total score, and
significant improvements were seen in 9 of the
12 individual Neuropsychiatric Inventory–NH
domains (p≤0.03).65 After 52 weeks, 45% of
patients showed a 30% or greater reduction in
Neuropsychiatric Inventory–NH total score, and
10 of the 12 individual Neuropsychiatric
Inventory–NH domains were significantly
improved over baseline.55 However, it should be
noted that due to the open-label design of this
study,55, 65 caution must be used in drawing
efficacy conclusions, especially since behavioral
improvements were seen for both active drug and
placebo in the donepezil nursing home studies.43, 57
The apparent lack of a significant treatment
difference between cholinesterase inhibitors and
placebo in the nursing home studies contrasts
with the significant behavioral benefits over
placebo in community-dwelling patients with
mild-to-moderate or moderate-to-severe
Alzheimer’s disease (Table 2).  Suggested
explanations for this lack of treatment effect
include the high rate of concomitant
psychotropic drug use in the nursing home
patients (approximately 60% to > 80%), which
may account for the behavioral improvements
seen in the placebo groups.  Indeed, in the study
of donepezil for moderate-to-severe Alzheimer’s
disease,47 which showed significant benefits of
donepezil over placebo for problem behaviors,
only 36–45% of the patients used psychotropic
agents at some point during the study.
Alternatively, it has been suggested that there is
an inherent difference between studying
Alzheimer’s disease–related behavior in patients
residing in different settings and, consequently, a
differential sensitivity of the Neuropsychiatric
Inventory in these settings.  In a recent review,
the authors noted that studies of cholinesterase
inhibitors in nursing home patients have yielded
mixed results and suggested that the efficacy
measures for community-dwelling patients may
not be appropriate for measuring outcomes in
nursing home patients.66 The authors suggested
that outcomes such as decreased hospital
admissions, prevented falls, reduced staff
turnover, and reduced use of pharmacologic
and/or physical restraints may be more useful
measures of efficacy in this population.
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Table 2.  (continued)
Mean ± SEM Change in NPI Scorea
Treatment Placebo Treatment
Group Group p Valueb Difference
-2.9 ± 1.6 +3.3 ± 2.1 0.02 6.2
-0.1 ± 0.7 +2.0 ± 0.7 <0.05 2.1
0.0 ± 0.8 <0.05 2.0
-4.6 +1.0 0.0005 5.6
-2.3 ± 1.9 -4.9 ± 1.9 NS 2.6d
-3.2 ± 1.3 -1.7 ± 1.4 NS 1.5
-1.4 +2.1 0.011 3.5
-0.1 ± 0.98 +3.7 ± 0.99 0.002 3.8
+0.5 +3.8 NS 3.3
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Safety
The adverse events reported most often for
patients taking cholinesterase inhibitors are
nausea, vomiting, and diarrhea.  Other less
common adverse events include weight loss,
insomnia, abnormal dreams, muscle cramps,
bradycardia, syncope, and fatigue.  Clinical
experience suggests that starting cholinesterase
inhibitor treatment at a low dosage and titrating
the dosage upward gradually, may decrease the
frequency of adverse events.67
Memantine
Memantine, an N-methyl-D-aspartate receptor
antagonist, received FDA approval for the
treatment of moderate-to-severe Alzheimer’s
disease in 2003.  Studies of memantine
monotherapy have shown that it provides
cognitive and functional benefits to patients in
late-stage disease.60 The effect of memantine
treatment on the behavioral symptoms of
Alzheimer’s disease have also been assessed.
In a study of memantine monotherapy for
moderate-to-severe Alzheimer’s disease, no
statistically significant treatment difference was
observed between patients treated with
memantine and those receiving placebo.60 Both
groups showed worsened behavioral symptoms
compared with baseline after 7 months of
treatment, although the worsening was markedly
less pronounced with memantine (Table 2).  In a
6-month study of memantine add-on treatment,
patients with moderate-to-severe Alzheimer’s
disease receiving long-term donepezil therapy
(mean 2.45 yrs) were randomly assigned to
receive either donepezil plus placebo or
donepezil plus memantine.59 At study end point,
total Neuropsychiatric Inventory scores remained
at baseline severity in patients who received add-
on memantine treatment, but increased from
baseline in patients receiving donepezil alone
(treatment difference p=0.002; Table 2).  In
recent post hoc analyses from this trial,
Neuropsychiatric Inventory domain scores for
agitation/aggression, irritability/lability, and
appetite or eating change were statistically
significant in favor of memantine at end point
(p≤0.045).68 Although not conclusive, these
results suggest that combined treatment with a
cholinesterase inhibitor and memantine may
provide additional benefits over each agent alone
in terms of treating the behavioral symptoms of
Alzheimer’s disease.
Despite not being specifically approved for
mild-to-moderate Alzheimer’s disease by the
FDA, a trial of memantine for patients in these
stages of the disease was performed.58 In this
study, 403 patients with mild-to-moderate
Alzheimer’s disease (MMSE score 10–22
inclusive) were randomized to memantine
monotherapy or placebo.  At 24 weeks, a
statistically significant difference was noted in
total Neuropsychiatric Inventory score in favor of
memantine (p=0.011; Table 2).
Safety
The adverse events reported most often for
patients receiving memantine include dizziness,
confusion, headache, and constipation.  Most
reported adverse events were mild to moderate in
severity.60, 69
Other Pharmacologic Treatments
Pharmacologic therapy for the more severe
behavioral symptoms of dementia, such as
delusions and hallucinations, has traditionally
included the conventional and atypical
antipsychotics.45 Recent reviews of studies
including these agents noted that comparative
data demonstrating the advantages and
disadvantages of antipsychotic drugs in dementia
are generally lacking.56, 70 Effectiveness of these
agents is also difficult to assess given the robust
placebo responses in these patients.70 Adverse
effects for conventional antipsychotics include
neurologic, cardiovascular, anticholinergic, and
weight gain effects.71 Specific neurologic adverse
events, such as tardive dyskinesia and other gait
disturbances, can increase the risk of falls and
hip fracture in this frail population.72, 73
A review of pharmacologic treatments for
neuropsychiatric symptoms of dementia
indicated that the atypical antipsychotics,
olanzapine and risperidone, have the best
evidence for efficacy, with minimal adverse
effects at lower doses.56 However, most of the
antipsychotic trials reviewed in that article
studied efficacy in nursing home residents or
hospitalized patients, and, when reported,
baseline Neuropsychiatric Inventory–NH scores
were much higher than those in the
cholinesterase inhibitor or memantine studies
(mean treatment group score range 32.6–44.2).74, 75
This suggests that these agents may be
particularly suited for more advanced behavioral
problems associated with dementia.  Of interest,
recent findings from the Clinical Antipsychotic
Trials of Intervention Effectiveness–Alzheimer’s
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Disease (CATIE-AD) trial, specifically designed
to assess the effectiveness of atypical
antipsychotics in patients with Alzheimer’s
disease, showed that the benefits of these agents
on behaviors such as psychosis, agitation, or
aggression, were in most cases offset by adverse
events.76 The authors concluded that physicians
and patients and/or their caregivers need to fully
consider the risk:benefit ratio with these agents
in order to optimize patient care.  In principle,
the combination of a low-dose atypical anti-
psychotic and either a cholinesterase inhibitor or
memantine might be beneficial for the treatment
of behavioral symptoms in patients with
Alzheimer’s disease, but such combinations have
not been systematically studied in placebo-
controlled, prospective, double-blind, randomized
trials.
Atypical antipsychotics have a more favorable
adverse-effect profile than that of conventional
agents,77 although there are conflicting reports of
whether they have fewer extrapyramidal
symptoms.78, 79 In the CATIE-AD trial, extra-
pyramidal symptoms were more common among
individuals receiving olanzapine (12%) and
risperidone (12%) than in those receiving
quetiapine (2%) or placebo (1%).76 However,
other adverse effects limit the utility of these
drugs because some of the atypical drugs have
the potential to exacerbate the cognitive and
functional symptoms of Alzheimer’s disease
because of their anticholinergic properties.23 In
addition, risperidone,80 olanzapine,81 and
aripiprazole82 have been shown to result in
cerebrovascular adverse events in dementia trials,
although the clinical results supporting this
association were not obtained from studies
designed to prospectively assess the cerebro-
vascular effects of these agents.83 Results from a
recent meta-analysis indicated no significant
difference in the risk of ischemic stroke among
patients with dementia treated with conventional
or atypical antipsychotics.84
Recently, the FDA determined that the
treatment of behavioral disorders in elderly
patients with dementia with atypical (second
generation) antipsychotic drugs is associated
with increased mortality.85 Because of these
findings, the FDA asked the manufacturers of
these drugs to include a black-box warning in
their labeling that describes this risk and notes
that these drugs are not approved for this
indication.  Boxed warnings are now included in
the prescribing information for these atypical
agents.85 The findings of the FDA are supported
by data from a recent meta-analysis of 15
randomized controlled trials, which showed that
atypical antipsychotic drugs may be associated
with increased mortality compared with
placebo.86 Of interest, results of another recent
study indicate that conventional antipsychotic
drugs are at least as likely as atypical agents to
cause death in elderly patients with dementia,
and that conventional antipsychotics should not
be used to replace agents discontinued due to the
FDA warning.87
As depression is a common symptom for
patients in the early stages of dementia,
antidepressant therapies have been used to treat
patients with Alzheimer’s disease.  The older
tricyclic antidepressants have proved to be of
limited value for patients with dementia because
of the anticholinergic adverse effects associated
with their use.  Selective serotonin reuptake
inhibitors have been shown to be better tolerated
than tricyclic antidepressants, and they help
alleviate the depressive symptoms of patients
with dementia,45 although no clear benefits on
neuropsychiatric symptoms have been reported
in controlled studies.56
Another common behavioral symptom of
Alzheimer’s disease is agitation.  In patients with
Alzheimer’s disease, agitation may be reduced by
treatment with mood-stabilizing agents.  Some
studies of carbamazepine indicate significant
benefits for agitation, whereas others studies are
less conclusive regarding the effects of
carbamazepine on behavioral symptoms.56, 67, 88–91
Likewise, studies of divalproex sodium have
yielded mixed efficacy results.56, 67, 92–94
Benzodiazepines may be used for the treatment
of agitation in some patients.  In a double-blind,
randomized, placebo-controlled trial investi-
gating the efficacy of the atypical antipsychotic
olanzapine and the benzodiazepine lorazepam in
treating dementia-associated agitation, both
drugs showed significant improvement over
placebo on agitation scales at 2 hours, which was
maintained at 24 hours for olanzapine only.95
Sedation, adverse events, and laboratory analyses
were not significantly different from those of the
placebo group for either drug.  Generally, only a
modest response to benzodiazepines is seen in
patients with Alzheimer’s disease, and other
disadvantages include sedation, tolerance, risk of
falls, and dependence.  Therefore, they may be
most useful in managing occasional nonpsychotic
agitation or anxiety, but they are not recom-
mended for the long-term management of
behavioral symptoms.56, 96
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Discussion
The behavioral symptoms of Alzheimer’s
disease tend to increase in prevalence and
severity as the disease progresses and frequently
precipitate nursing home placement.  Recognizing
and treating behavioral symptoms early with
nonpharmacologic and/or pharmacologic
treatments can slow symptom progression.
Appropriate treatment of Alzheimer’s disease can
also reduce the distress to patients and caregivers
and may delay placement of a patient in a
residential care facility or nursing home.97, 98
Prospective, randomized, placebo-controlled
trials have shown that the cholinesterase
inhibitors, donepezil and galantamine, can
provide behavioral benefits for patients with
mild-to-moderate Alzheimer’s disease.  In
addition, donepezil treatment has been shown to
improve behavioral symptoms in patients with
moderate-to-severe Alzheimer’s disease.
Memantine treatment as an add-on to long-term
donepezil therapy has also been shown to benefit
patients with moderate-to-severe Alzheimer’s
disease, and memantine monotherapy has
provided behavioral benefits in patients with
mild-to-moderate Alzheimer’s disease.  In
contrast, results from randomized, placebo-
controlled studies of cholinesterase inhibitors in
nursing home patients are less convincing,
mainly due to the robust placebo response and
the uncertain sensitivity of the Neuropsychiatric
Inventory as a measure of behavioral problems in
these patients.
When considering the effects of cholinesterase
inhibitors and memantine on behavior, the
benefits, although significant, are often high-
lighted as generally being small.56, 64 As shown in
Table 2, this is often the case.  However, even
when the reported changes in Neuropsychiatric
Inventory scores seem numerically low in
relation to the overall scale range, the percentage
change from baseline score can occasionally
show more promise.  For example, in one study,
among patients with mild-to-moderate Alzheimer’s
disease, those treated with donepezil showed a
2.9-point reduction in Neuropsychiatric
Inventory score, which seems negligible in
relation to the overall scale range of 0–120.49
Nevertheless, when considered in relation to the
change from baseline scores, the donepezil-
treated patients showed a 20% improvement in
behavioral symptoms, whereas placebo-treated
patients showed a 22% worsening of behavioral
symptoms over the same time period.  When
viewed in this manner, the possible benefits of
these agents are somewhat clearer.
In addition to cholinesterase inhibitors and
memantine, other pharmacologic agents, such as
antipsychotics, antidepressants, mood-stabilizing
agents, and benzodiazepines, can assist with
problem behaviors.  Indeed, many of these agents
are effectively used to treat the behavioral
symptoms of Alzheimer’s disease, particularly in
patients with severe behavioral problems.
However, none of these agents is approved by the
FDA for the specific treatment of the behavioral
symptoms of Alzheimer’s disease.  Moreover, use
of these agents may be limited by uncertain
efficacy, poor safety profiles, and/or potential
anticholinergic effects, and many are not
recommended for long-term management of
behavioral problems.
Conclusion
Nonpharmacologic strategies remain the
cornerstone of the management of Alzheimer’s
disease–related behavioral symptoms.  However,
when pharmacologic intervention is deemed
necessary for problem behaviors, it is important
that physicians, pharmacists, and nurses
recognize the possible beneficial effects of
cholinesterase inhibitors, either alone or with
memantine as appropriate for the stage of
disease, and consider these agents as a first-line
option for early pharmacologic treatment of the
behavioral symptoms of Alzheimer’s disease.
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